Oral Cancer Drugs on Medicare: Part B vs Part D

Cancer treatment has moved increasingly from the infusion chair to the pill bottle. Many targeted therapies now come as oral drugs you take at home. That is a real convenience, but it creates one of the most confusing coverage questions in all of Medicare, because whether an oral cancer drug is covered under Part B or Part D is not obvious, and the answer changes what you pay. Getting clear on which part covers your drug, and how your supplemental coverage interacts with it, is essential when you are facing an expensive course of treatment.

Bryce's Take

The oral cancer drug question is one of the trickiest I deal with, because the same category of treatment can land under Part B or Part D depending on the exact drug. What I want clients to understand is how their supplemental coverage protects them: a good Medigap plan can nearly wipe out the cost of a Part B drug, while the $2,000 cap protects you on the Part D side. If you or a loved one is starting an oral cancer therapy, let us pin down which pathway your drug falls under and make sure your coverage actually shields you.

Why the Part B vs Part D split exists

Historically, chemotherapy was given by infusion in a clinic, which put it squarely under Part B, the medical side that covers provider-administered drugs. When oral versions of some of these drugs arrived, Medicare kept certain oral anticancer drugs under Part B, generally those that have an intravenous equivalent, so that the pill and the infusion would be treated similarly. Most other oral cancer drugs, including many newer targeted therapies, are covered under Part D, your prescription drug coverage. The result is a split that depends on the specific drug rather than a simple rule you can apply across the board.

How the two pathways differ in what you pay

The part that covers your drug changes the cost structure entirely.

A side-by-side view

How Medigap interacts with Part B drugs

If your oral cancer drug is covered under Part B and you have Original Medicare with a comprehensive Medigap plan like Plan G, your Medigap plan generally picks up the Part B coinsurance, which can bring your out-of-pocket cost for that drug down close to zero after the annual Part B deductible. This is one of the underappreciated strengths of Medigap: it protects you against the 20 percent Part B coinsurance that would otherwise apply with no cap under Original Medicare alone. For a very expensive Part B drug, that difference is enormous.

How an Advantage plan interacts with each

Under a Medicare Advantage plan, both Part B and Part D drugs run through the plan's cost-sharing. A Part B cancer drug is subject to the plan's medical cost-sharing and counts toward the plan's annual out-of-pocket maximum, while a Part D drug runs through the plan's drug coverage and the separate $2,000 Part D cap. Advantage plans also commonly require prior authorization for cancer drugs, and the plan's network can determine which cancer centers and specialty pharmacies you can use. These are important considerations if you are choosing between Advantage and Original Medicare plus Medigap while facing cancer treatment.

Figuring out your specific situation

Because the split depends on the specific drug, the only reliable way to know your costs is to identify exactly which drug you will take and confirm whether it is a Part B or Part D drug, then look at how your supplemental coverage handles that pathway. The $2,000 Part D cap and, for Part B drugs, a strong Medigap plan or an Advantage out-of-pocket maximum are the tools that limit your exposure. This is a situation where getting the details right genuinely matters, and where a conversation can save real money and stress.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.